CN1997364A - 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗 - Google Patents

显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗 Download PDF

Info

Publication number
CN1997364A
CN1997364A CNA2004800301164A CN200480030116A CN1997364A CN 1997364 A CN1997364 A CN 1997364A CN A2004800301164 A CNA2004800301164 A CN A2004800301164A CN 200480030116 A CN200480030116 A CN 200480030116A CN 1997364 A CN1997364 A CN 1997364A
Authority
CN
China
Prior art keywords
alkyl
group
compound
substituted
unbranched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800301164A
Other languages
English (en)
Chinese (zh)
Inventor
J·安特尔
P-C·格雷戈里
H·沃尔德克
G·克劳瑟
J·H·M·兰格
K·克雷泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of CN1997364A publication Critical patent/CN1997364A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800301164A 2003-10-24 2004-10-22 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗 Pending CN1997364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103961.3 2003-10-24
EP03103961 2003-10-24
EP03103967.0 2003-10-27

Publications (1)

Publication Number Publication Date
CN1997364A true CN1997364A (zh) 2007-07-11

Family

ID=34486362

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800301164A Pending CN1997364A (zh) 2003-10-24 2004-10-22 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗
CNA2004800300871A Pending CN1921849A (zh) 2003-10-24 2004-10-22 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004800300871A Pending CN1921849A (zh) 2003-10-24 2004-10-22 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗

Country Status (13)

Country Link
EP (1) EP1680106B1 (https=)
JP (1) JP2007509110A (https=)
CN (2) CN1997364A (https=)
AR (1) AR046132A1 (https=)
AT (1) ATE438394T1 (https=)
AU (1) AU2004283055A1 (https=)
BR (1) BRPI0415463A (https=)
CA (1) CA2543342A1 (https=)
DE (1) DE602004022445D1 (https=)
MX (1) MXPA06004390A (https=)
RU (1) RU2006117639A (https=)
TW (1) TW200528102A (https=)
WO (1) WO2005039566A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731418A (zh) * 2012-07-15 2012-10-17 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
WO2020103856A1 (en) * 2018-11-20 2020-05-28 Shanghaitech University Mmpl3 inhibitors, compositions and uses thereof
CN117551046A (zh) * 2023-11-17 2024-02-13 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002193A (es) * 2005-08-17 2008-03-25 Solvay Pharm Gmbh Metodos para usar compuestos inhibidores del canal de potasio.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74367C2 (uk) * 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
SK287592B6 (sk) * 2001-03-22 2011-03-04 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie
HUP0401567A3 (en) * 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
HRP20030913A2 (en) * 2001-09-21 2004-06-30 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JP2007506654A (ja) * 2003-06-20 2007-03-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類
AU2004283903B2 (en) * 2003-10-20 2010-12-02 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives as cannabinoid receptor modulators
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731418A (zh) * 2012-07-15 2012-10-17 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN102731418B (zh) * 2012-07-15 2015-03-11 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
WO2020103856A1 (en) * 2018-11-20 2020-05-28 Shanghaitech University Mmpl3 inhibitors, compositions and uses thereof
CN113166068A (zh) * 2018-11-20 2021-07-23 上海科技大学 MmpL3抑制剂、组合物及其用途
US11655238B2 (en) 2018-11-20 2023-05-23 Shanghaitech University MMPL3 inhibitors, compositions and uses thereof
CN113166068B (zh) * 2018-11-20 2024-08-16 上海科技大学 MmpL3抑制剂、组合物及其用途
CN117551046A (zh) * 2023-11-17 2024-02-13 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Also Published As

Publication number Publication date
DE602004022445D1 (de) 2009-09-17
BRPI0415463A (pt) 2006-12-19
AR046132A1 (es) 2005-11-23
AU2004283055A1 (en) 2005-05-06
MXPA06004390A (es) 2006-06-14
EP1680106A1 (en) 2006-07-19
EP1680106B1 (en) 2009-08-05
CA2543342A1 (en) 2005-05-06
TW200528102A (en) 2005-09-01
ATE438394T1 (de) 2009-08-15
WO2005039566A1 (en) 2005-05-06
RU2006117639A (ru) 2007-12-10
JP2007509110A (ja) 2007-04-12
CN1921849A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
US20240261288A1 (en) Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
TWI309650B (en) Heterocyclic inhibitors of erk2 and uses thereof
US20230059381A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
JP2004532235A (ja) 望ましくないサイトカイン活性に関連する疾患を治療するのに有用なトリアゾール化合物
US20050124660A1 (en) Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
JP2004528351A (ja) 望ましくないサイトカイン活性に関連する疾患を治療するのに有用なトリアゾール化合物
JP2016540017A (ja) ｓＧＣ刺激物質
CA2966303A1 (en) Substituted pyridines as bromodomain inhibitors
JP2020526557A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP6082457B2 (ja) Ｇｐｒ１７受容体調節因子
US20240277852A1 (en) Inhibitors and degraders of pip4k protein
CN109862893A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
MXPA06004434A (es) Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.
JP5731538B2 (ja) Ｃｒｔｈ２モジュレーター
US9382208B1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2
CN1997364A (zh) 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗
TW201630607A (zh) 西格馬受體配位子於骨關節炎之用途
US10538491B2 (en) 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
WO2025038783A1 (en) Adenosine ligands for the treatment of neurological disorders or chronic heart failure
US20130289047A1 (en) Heteroarylthio derivatives and analogues
CN107207477A (zh) 用于治疗病毒性疾病的亚氨基糖
AU732722B2 (en) 2-{4-{4-(4,5-dichloro-2- methylimidazol-1-yl)butyl} -1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use
HK1101275A (en) Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
WO2026030391A1 (en) Subunit-selective n-methyl-d-aspartate receptors modulators and uses related thereto

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101275

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070711

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1101275

Country of ref document: HK